1999;282:2340 6. S5.1.5.2-58. Buber J, Goldenberg I, Moss AJ, et al. Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with non- ischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2012;60:749 55. S5.1.5.2-. 59 Investigators in TAvIDAA comparison of antiarrhythmic- drug therapy with implantable defibrillators in patients resus- citated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576 83. S5.1.5.2-60. Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 2003;42:81 7. S5.1.5.2-61. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardio- myopathy and in patients with implantable defibrillators: mortal- ity data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007;153:573 8. S5.1.5.2-62. Goldberger JJ, Subacius H, Schaechter A, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1228 33. S5.1.5.2-63. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248 61. S5.1.5.2-64. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvas- tatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231 9. 5.2. Preventing SCD With HF Medications S5.2-1. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management CLINICAL STATEMENTS AND GUIDELINES of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 